Welcome to our dedicated page for Caredx news (Ticker: CDNA), a resource for investors and traders seeking the latest updates and insights on Caredx stock.
CareDx, Inc. (Nasdaq: CDNA) is a precision medicine company in the medical laboratories industry that focuses on transplant patients and caregivers. The company describes itself as “The Transplant Company” and emphasizes genomics‑based information, non‑invasive molecular testing, and digital health technologies for heart, kidney, and lung transplantation. This news page brings together company announcements and disclosures that illustrate how CareDx develops and commercializes transplant‑focused diagnostics and solutions.
Readers can expect news related to financial results, where CareDx reports revenue across testing services, product revenue, and patient and digital solutions revenue. The company issues press releases on quarterly and preliminary annual performance, highlighting trends in testing services volume and segment‑level revenue. These updates provide context on how its transplant‑focused offerings are used in clinical practice.
CareDx also publishes clinical and scientific updates, including data from the Surveillance HeartCare Outcomes Registry (SHORE) and other transplant studies. These releases describe how HeartCare, AlloSure Heart, and related molecular tests are evaluated as biomarkers for rejection risk, graft dysfunction, and treatment response in heart and kidney transplantation. Product‑focused news, such as the introduction of HistoMap Kidney and other molecular assays, further illustrates the company’s emphasis on transplant diagnostics.
Additional news items cover corporate and governance developments, such as leadership appointments, board changes, equity inducement grants under Nasdaq Listing Rule 5635(c)(4), and participation in investor conferences. Together, these updates offer investors, clinicians, and other stakeholders a consolidated view of CareDx’s activities in precision transplant medicine. For ongoing insight into CDNA, this page serves as a central source for company press releases and related disclosures.
CareDx Appoints Art Torres to Board of Directors
CareDx, Inc. (Nasdaq: CDNA) announced the appointment of Art Torres to its Board of Directors. Torres, a former California state senator and advocate for organ transplantation, brings extensive expertise in regenerative medicine and health equity. He is currently involved with several organizations, including the California Institute for Regenerative Medicine and One Legacy. His addition to the board is seen as a move to strengthen CareDx's commitment to improving support for transplant patients across diverse communities.
CareDx, a precision medicine company, announces its participation in two upcoming healthcare conferences. The first is the 2021 Wells Fargo Healthcare Conference on September 9, 2021, at 3:20 p.m. Eastern Time, with a live webcast available on the company's investor relations site. The second event is the H.C. Wainwright 23rd Annual Global Investment Conference, where CareDx will present on September 13, 2021, at 7:00 a.m. Eastern Time. CareDx specializes in solutions for transplant patients, offering services and products that enhance the pre- and post-transplant experience.
CareDx launches AlloSeq cfDNA Research Service and showcases leadership at ESOT 2021.
On August 26, 2021, CareDx, Inc. (Nasdaq: CDNA) announced its presence at the European Society of Organ Transplantation (ESOT) conference with six abstracts and an upcoming symposium. The AlloSeq cfDNA service detects donor-derived cfDNA in less than 24 hours and aims to expand research internationally from its Stockholm lab. The ESOT symposium on August 29 will highlight advanced strategies for allograft surveillance, featuring experts in the field.
CareDx, Inc. (Nasdaq: CDNA) reported second-quarter 2021 financial results with total revenue of $74.2 million, a 77% increase year-over-year. Testing services revenue reached $64.9 million, up from $36.3 million in Q2 2020. Notably, the company has generated approximately 37,400 AlloSure and AlloMap patient results this quarter. Despite a net loss of $1.9 million, an improvement from $6.6 million in the previous year, the company reported a non-GAAP net income of $5.9 million. CareDx raised its 2021 revenue guidance to a range of $280-$290 million.
CareDx, Inc. (NASDAQ: CDNA) has announced the enrollment of the first patient in the ACROBAT study, which investigates the potential of the AlloHeme testing tool in predicting relapse for patients undergoing allogeneic hematopoietic cell transplants. This multicenter study aims to evaluate the effectiveness of AlloHeme, which uses next-generation sequencing to monitor donor and recipient cell levels, enhancing patient surveillance post-transplant. With around 10,000 such transplants annually in the U.S., the outcome of this study could significantly impact patient care and surveillance in this area.
CareDx, Inc. (Nasdaq: CDNA) announced it will report its financial results for Q2 2021 after market close on July 29, 2021. A conference call hosted by company management will follow at 1:30 p.m. PT (4:30 p.m. ET). Investors can participate by calling 877-705-6003 domestically or 201-493-6725 internationally, using Conference ID: 13721182. Live webcasts will be available on CareDx's investor relations website.
CareDx specializes in precision medicine solutions for transplant patients, emphasizing genomics-based information throughout the pre- and post-transplant journey.
CareDx has launched the AlloCare app on the Android Play Store, complementing its availability on iOS, aimed at assisting organ transplant patients in managing their health pre-and-post-transplant. This user-friendly app offers features such as medication management, lab appointment scheduling, and biometric tracking, effectively doubling the total addressable user base. The app's design was heavily influenced by input from transplant recipients and patient organizations, ensuring it meets the specific needs of users, whether they are awaiting a transplant or years post-operation.
CareDx, Inc. (Nasdaq: CDNA) has announced the appointment of Dr. Hannah Valantine to its Board of Directors. Dr. Valantine, a Professor at Stanford and former Chief Scientific Officer at NIH, is recognized for her leadership in transplant medicine and diversity initiatives. She has collaborated with CareDx on important publications related to transplant biomarkers. Her extensive clinical background and innovative approach will enhance CareDx's Scientific Advisory Committee and support the company's mission to improve patient care in the transplant community.
Reg Seeto, President and CEO of CareDx (Nasdaq: CDNA), will discuss telehealth innovations for transplant patient care at the AAKP 2021 Summit on June 17, 2021. The presentation, titled Improving Access to Transplant Care, highlights solutions like RemoTraC, AlloCare, and Tx Connect, which have become essential, especially during the COVID-19 pandemic. Seeto emphasizes that such technologies enhance patient access and care throughout the transplant journey. AAKP advocates for patient-centered innovations in the kidney care community.
CareDx, Inc. (Nasdaq: CDNA), a leader in precision medicine for transplant patients, will participate in the Raymond James 2021 Human Health Innovation Conference on June 21, 2021, at 10:40 a.m. Eastern Time. The event will be accessible via a live webcast on the company's investor relations site. CareDx specializes in developing clinically differentiated healthcare solutions and is known for providing genomics-based information for transplant patients. Further details can be found on their website.